A Peek Into The Market Before The Trading Starts

Pre-open movers US stock futures are higher this morning, as investors are awaiting the third release of US Q1 gross domestic product and data on May durable-goods orders. Futures on the Dow Jones Industrial Average surged 20 points to 11,996.00 and futures on the S&P 500 stock index rose 1.80 points to 1,278.80. Nasdaq 100 futures jumped 9.75 points to 2,247.25. A Peek Into Global Markets Asian markets ended higher, with Japan's Nikkei Stock Average surging 0.8541%, Australia's S&P/ASX 200 moving up 0.08% and China's Shanghai Composite surging 2.16%. Hong Kong's Hang Seng Index rose 1.8972% and India's Sensex jumped 2.89%. European markets were higher today. The STOXX Europe 600 Index has gained 0.33%, London's FTSE 100 Index moved up 0.93%, German DAX 30 index rose 0.76% and France CAC 40 index surged 0.75%. Broker Recommendation Analysts at HSBC Securities downgraded Tiffany & Co TIF from “overweight” to “neutral.” The target price for Tiffany has been raised from $75 to $81. Tiffany shares dropped 0.21% to close at $76.27 yesterday. Breaking news

• In the latest chapter of litigation between the two technology giants, Apple AAPL has filed a lawsuit against Samsung Electronics in South Korea over smartphone patents. To read the full news, click here.
• Aegerion Pharmaceuticals, Inc. AEGR announced the pricing of the underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $15.50 per share. To read the full news, click here.
• HTC EVO 3D and HTC EVO View 4G™, debut today, exclusively from Sprint S. HTC EVO 3D, America's first glasses-free 3D phone will cost $199.99 and HTC EVO View 4G, the first 4G-enabled tablet in the United States, will cost $399.99. To read the full news, click here.
• ViroPharma Incorporated VPHM earlier today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years. To read the full news, click here.